Doron Therapeutics Announces First Patients Dosed in Phase 3 Study of MOTYS (PTP-001) for the Treatment of Osteoarthritis of the Knee

[#item_full_content]CHAPEL HILL, N.C.–(BUSINESS WIRE)– #AlessandraPavesio–The Phase 3 study is a global trial to evaluate improvements in both pain and function for up to 12 months following a MOTYS injection.